H
ip fractures are associated with substantial morbidity and mortality. The costs of surgery and rehabilitation are a burden on public health resources, especially because the incidence of hip fracture increases as the population ages (1, 2) . Most hip fractures are related to osteoporosis, and treating accelerated bone loss may therefore be an important strategy to prevent hip fractures (3) .
Thiazide diuretics are widely used as antihypertensive agents. They are inexpensive and effective and have few important adverse effects (4) . Thiazides are thought to protect against age-related bone loss by reducing urinary calcium excretion (5) . This bone-sparing effect could lead to reduced fracture incidence in patients treated for hypertension. Several epidemiologic studies have examined the effect of thiazides on bone mineral density and fracture incidence. Although bone mineral density was found to be increased in thiazide users, the difference was often small (6 -12) . Thiazides were found to have a protective effect on hip fracture in most studies (9, (12) (13) (14) (15) (16) (17) , but occasionally an increased risk was found (18) . Most of the studies, however, had limitations. Some studies included detailed drugdispensing data but limited information on potential confounders and effect modifiers (15, 18, 19) . Other studies had small patient samples or used only baseline interview data on thiazide use (9, 12, 16, 20) without accounting for timing of thiazide use (14, 20, 21) . Detailed information on thiazide dose and duration of use was often absent or unreliable because no data on day-to-day use were available. Because of these limitations, it is still unclear how long thiazides have to be taken to affect fracture incidence and how long this effect persists after thiazide use is discontinued.
We conducted a prospective, population-based cohort study using detailed drug-dispensing information, as well as extensive information on potential risk factors, to examine the association between current and past use of thiazides and the incidence of hip fractures in men and women 55 years of age and older. We also studied the effect of discontinuing thiazide use on fracture risk.
METHODS

Study Sample
This study was conducted as part of the Rotterdam Study, a prospective, population-based cohort study on the occurrence and determinants of disease and disability in elderly persons (22) . In 1990, all inhabitants of Ommoord, a suburb of Rotterdam in the Netherlands, who were 55 years of age or older and had lived in the district for at least 1 year were invited to participate in the study. Of the 10 275 eligible persons, 7983 (78%) participated. Participants gave informed consent and permission to retrieve information from medical records. At baseline, between 1990 and 1993, trained interviewers administered an extensive questionnaire covering socioeconomic background and medical history, among other topics, during a home interview. During subsequent visits to the study center, additional interviewing, laboratory assessments, and clinical examinations were performed. Information on vital status is obtained at regular time intervals from the municipal authorities in Rotterdam. The Medical Ethics Committee of the Erasmus MC, Rotterdam, the Netherlands, approved the study.
For the present study, all participants were followed from 1 June 1991 until they had an incident hip fracture, died, or reached the end of the study at 31 December 1999, whichever came first.
Exposure Definition
In the research area, there are 7 fully computerized pharmacies that are linked to 1 network. During the study, all participants filled their prescriptions in 1 of these 7 pharmacies. Data on all dispensed drugs since 1 January 1991 are available in computerized format on a day-to-day basis. The data include the date of prescribing, the total amount of drug units per prescription, the prescribed daily number of units, product name, and the Anatomical Therapeutic Chemical (ATC) code (23) .
The exposure of interest included plain thiazides and thiazides combined with potassium and potassium-sparing agents. Although formally not a thiazide, chlorthalidone was included because it has a similar effect on calcium excretion. In a previous study, these 2 diuretics did not differ (12) . Therefore, we did not distinguish between them.
When a hip fracture occurred, the date was defined as the index date and the cumulative duration of use of thiazides on that date was calculated for each participant. Current use was defined as use of thiazides at the index date and was expressed as the number of consecutive days of use. Past use was defined as use of thiazides after baseline and before but not on the index date itself. Past use was expressed as the number of days since discontinuing use. To study the effect of duration of thiazide use, exposure at the index date was divided into 7 mutually exclusive categories, defined a priori: never use, current use for 1 to 42 days, current use for 43 to 365 days, current use for more than 365 days, discontinuation of use since 1 to 60 days, discontinuation of use since 61 to 120 days, and discontinuation of use since more than 120 days. We selected the first duration of 42 days because in the first 6 weeks of thiazide use, the decrease in circulating volume can cause dizziness and relative cerebral ischemia. We anticipated that this might be associated with a transiently increased risk for falls that should be distinguished from a potentially protective effect after prolonged use. After 42 days, the circulating volume in most patients is within normal limits (24) . The duration of more than 365 days was chosen because trials on incidence of nonvertebral fractures with use of antiosteoporotic agents, such as bisphosphonates, all had at least 1 year of follow-up as well. Finally, the duration of 60 days after discontinuing use was chosen because it was used in an earlier study (15) .
We expressed the prescribed daily dosage during current use at the index date as a proportion of the defined daily dosage (25) . The defined daily dosage of thiazide diuretics is the standard recommended adult daily dosage for treating patients with hypertension in the Netherlands.
To avoid potential misclassification of exposure at baseline, we ensured that all participants had potential pharmacy data for at least 5 months before baseline.
Outcome Definition
The study participants' general practitioners report all fatal and nonfatal events, such as fractures, through a computerized system. These data cover about 80% of the study sample. For participants who were not covered in this system, research physicians performed annual checks on the complete medical records of all general practitioners in the Rotterdam Study.
Two research physicians independently coded all fractures that occurred during the study period using the International Classification of Diseases, 10th revision (ICD-10) (26) . A medical expert in the field who was unaware of patients' history and medication use (including thiazides) reviewed all coded events for a final classification. Fractures with ICD-10 codes S72.0, S72.1, and S72.2 were included, but pathologic hip fractures (M84.4) and fractures in prosthetic hips (M96.6) were excluded.
Cofactors
The following baseline patient characteristics, all determined by interview, were individually assessed as potential confounders: age, sex, score on the Mini-Mental State Examination (Ͻ26 points) (27) , use of a walking aid, any fracture in the past 5 years, history of hysterectomy, thyroid disease, frequency of falling (Նonce per month), current smoking, intake of alcohol (Ͼ2 g/d), and dizziness. Participants were interviewed about a previous diagnosis of Parkinson disease or use of antiparkinsonian drugs and were screened for symptoms of Parkinson disease by study physicians at the research center. Diabetes mellitus was defined as the use of glucose-lowering medication or a random or postload serum glucose level of 11.1 mmol/L (200 mg/dL) or greater. Hypertension (systolic blood pressure Ͼ 160 mm Hg, diastolic blood pressure Ͼ 95 mm Hg, or use of any antihypertensive drug), visual impairment in 1 or both eyes, and body mass index (kg/m 2 ) were
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Thiazide diuretics reduce urinary calcium excretion and increase bone mineral density, but do they prevent bone fractures?
Contribution
In this population-based cohort study of 7891 older adults, patients taking thiazides for more than 1 year had a lower risk for hip fracture than those not taking thiazides (hazard ratio, 0.46 [95% CI, 0.21 to 0.96]). Within 4 months of stopping thiazides, the risk for hip fracture returned to its pretreatment value.
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-The Editors
Article Thiazides and Hip Fractures measured at the research center. Presence of peripheral arterial disease was measured (as described elsewhere [28] ) by using a single measurement of systolic blood pressure taken at both the left and the right posterior tibial artery. The ratio of the systolic blood pressure at the ankle to the systolic blood pressure at the arm was calculated for each leg. Peripheral arterial disease was considered present when the blood pressure at the arm was lower than 0.9 mm Hg on at least 1 side. Lower-limb disability was assessed by using a modified version of the Stanford Health Assessment Questionnaire (29) and by calculating the mean score of answers to questions about rising, walking, bending, and getting in and out of a car (30) . A score of 0 indicates no disability, a score between 0 and 1 indicates mild disability, and a score of more than 1 indicates severe disability. Intake of calcium was adjusted for the total caloric intake according to the method of Willett and associates (31) . Bone mineral density of the femoral neck was measured by using dual-energy x-ray absorptiometry (DPX-L densitometer, Lunar Corp., Madison, Wisconsin), as described elsewhere (32) . Bone mineral density was stratified by dividing the study sample at the median observation (0.71 g/cm 2 ). Use of other medications, such as corticosteroids, benzodiazepines, antidepressants, antihistamines, opioids, antacids, antipsychotics, statins, and estrogens, was analyzed as a potential confounder.
Statistical Analysis
Since exposure to thiazides may vary over time, we calculated risks for hip fracture with a Cox proportional hazards model (33) , with the exposure represented by timevarying covariates. The model compared the exposure to thiazides on the index date of each participant with an incident hip fracture with all other participants in the cohort who were alive and at risk for hip fracture at the index date. We also used time-dependent categorical variables to compare duration of current use with time since last use. The 7 exposure categories of continuous use in days are represented in the model by 6 dummy variables with "never use" as a reference category. Use of other prescribed drugs was also analyzed as a time-dependent categorical variable. We did a trend analysis on the exposure categories for current use.
To adjust for potential confounders, cofactors associated with the occurrence of hip fracture were included in the age-and sex-adjusted model if doing so caused a change in the point estimate of more than 5%. Because bone mineral density is a potential intermediate factor in the cause-effect relationship of thiazides and hip fractures, we selected only participants who did not use thiazides at baseline to study effect modification by femoral neck bone mineral density. To study whether there was a daily doseeffect relationship for current users, we divided daily dosage into equal to or less than 1.0 defined daily dosage and higher than 1.0 defined daily dosage and tested the effect of low-dosage use and high-dosage use against no use in separate regression analyses. To test an earlier suggestion of effect modification by low calcium intake (13), we also ran separate regression analyses for participants with the lowest tertile of calcium intake at baseline (Յ958 mg/d) versus participants with higher intake.
Multiple imputation was used to impute missing information for confounding variables. Five imputation values were calculated on the basis of the posterior predictive distribution of the missing values, and 5 complete data sets were created. On each complete set, the statistical analyses were performed and the point estimates of the 5 data sets were combined to form 1 average summary statistic. The variance of the summary statistic is calculated from the within-imputation variance and the between-imputation variance. The combined variance accounts for the uncertainty introduced by estimating the missing values (34) . All analyses were performed with SAS software, version 8.2 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Eighty-four participants died and 8 participants had an incident hip fracture before 1 June 1991. Therefore, the study sample included 7891 participants. During a total follow-up of 58 009 person-years, 281 hip fractures occurred. Table 1 shows baseline characteristics for the participants with hip fractures and the entire study sample, as well as the percentage of missing values for the variables. When included in a Cox proportional hazards model with age and sex, body mass index, lower-limb disability, current smoking, and estrogen use caused a change in the point estimate of 5% or more. These variables were therefore included in the final model. At baseline, thiazide users were more likely to be disabled; have a history of dizziness, diabetes mellitus, and frequent falling; and have had previous fractures in the past 5 years, but these factors did not change the point estimate by 5% or more.
The risk for hip fracture for ever use of thiazides (yes or no) was decreased but did not reach statistical significance (hazard ratio, 0.94 [95% CI, 0.72 to 1.24]). The risk for hip fracture with current use of thiazides, regardless of duration of use, was also not statistically significant (hazard ratio, 0.71 [CI, 0.47 to 1.06]). When duration of current thiazide use (in months) was used as a continuous variable, there was a statistically significant inverse association between increased duration and risk for hip fracture (hazard ratio, 0.99 [CI, 0.97 to 0.99]). Table 2 shows that with increasing duration of consecutive use among current users, the adjusted risk for hip fracture was statistically significantly reduced to 0.46 for persons exposed to thiazides for more than 1 year. Although the risk was lower among persons taking the lowest dose, the difference was not significant. We assessed whether the protective effect of thiazides persisted after discontinuing thiazide use and found a nonstatistically significant risk reduction up to 120 days, after which the hazard ratio returned to 1.0 (Figure) .
The strongest protective effect was found in participants older than 80 years of age, but the difference between this group and participants younger than 80 years of age was not statistically significant. The effect of long-term thiazide use did not differ in participants with lower or higher bone mineral density. Participants with a higher intake of calcium had a somewhat larger risk reduction ( Table 3) . Because the study included few men with hip fracture, there was insufficient power to study effect modification by sex.
To adjust for potential misclassification of duration of thiazide use at the start of the study, we also did an analysis in which we excluded all participants (35 case-patients, 849 controls) who used thiazides at baseline (self-reported users and pharmacy data-derived users) and participants with less than 365 days of follow-up. We still found a 30% reduction in incident hip fractures, but because of smaller numbers of participants, this was no longer statistically significant (hazard ratio, 0.72 [CI, 0.29 to 2.15]).
DISCUSSION
In this study, long-term use of thiazides was associated with a lower risk for hip fractures. Although this associa- tion was already visible after short-term use, the risk reduction reached statistical significance only after 1 year of continuous use. This protective effect occurred independently of thiazide dose. After discontinuation of thiazide treatment, the protective effect disappeared after 4 months. Because our study sample was predominantly female, we could not study effect modification by sex.
With the exception of 1 case-control study in which thiazides were associated with an increased risk for hip fracture (18) , several other observational studies found that thiazide use is associated with a lower incidence of hip fractures (12, 13, 15, 16, 19) . Few studies have investigated the duration of the protective effect of thiazides. A previous study (15) found a decreased risk for fracture for up to 2 months after discontinuing use, and a case-control study found an increased risk for hip fracture for any past use (13) . We more precisely assessed the duration of the protective effect of thiazides after discontinuation of use and found a risk reduction for up to 4 months after discontinuation.
Several studies published over the past decades have discussed the mechanisms by which thiazides might protect against hip fracture. First, thiazides can reduce renal calcium excretion, thereby creating a positive calcium balance (5, 35) . Second, by inducing a metabolic alkalosis, thiazides can inhibit bone resorption (36, 37) . Furthermore, in vitro studies showed that thiazides directly inhibit osteocalcin secretion of osteoblast-like cells (38, 39) . Transbøl and colleagues (21) found an effect of thiazides on bone mineral density only in the first 6 months of use, after which the bone mineral density of thiazide users and placebo users did not differ statistically significantly. Other studies, including a randomized, controlled trial, found protective effects of thiazides on bone mineral density (8, 9, 11), but these effects were often small. We could not study the effect of thiazides on bone mineral density because we had only cross-sectional data. However, if we adjusted for cross-sectionally measured bone mineral density in 1993, 2 years after the study began, the effect remained. When we investigated effect modification by calcium intake, we observed a trend toward a larger thiazide effect for participants with a higher calcium intake. This might suggest that creating a positive calcium balance is not the only mechanism by which thiazides affect hip fracture risk, because participants with moderate to high calcium intake also benefit from thiazides.
Several aspects of validity need to be discussed. Selection bias is unlikely to have occurred because our study was prospective and population-based. Although nonparticipants of the Rotterdam Study were slightly older (on aver- All estimates were adjusted for age, sex, body mass index, lower-limb disability, current smoking, and estrogen use. *P ϭ 0.05 for trend of current use. age, 73 vs. 70 years of age), it is very unlikely that participation was conditional on exposure to thiazides. Information bias is also unlikely, since exposure data were gathered before disease onset. We used pharmacy records to avoid potential misclassification of exposure, which was the main concern in earlier studies that defined exposure as use of thiazides at a baseline interview. Because we had access to independent and reliable information about drug exposure, in particular duration of use and past use, we could investigate the effect of thiazides for different periods of use. It is also unlikely that confounding explains our results, because we adjusted for many known confounders. It is well known that thiazides can enhance calcium metabolism, but it is unlikely that general practitioners prescribed thiazides preferentially to patients to lower their hip fracture risk during the study period. Confounding by indication cannot explain our results, because thiazides were prescribed somewhat more frequently to patients at a higher risk for hip fracture. This would tend to negate the protective effect and even indicate a spurious risk increase. Because there were few men in our study, the effects of thiazides on hip fracture risk in women probably dominate our results. Therefore, it is possible that these effects are somewhat different in men. Hypertension is a very common medical problem that often requires long-term treatment. Thiazides are still recommended as first-choice antihypertensive agents, but the prescription rate for these drugs has decreased over the past decade (40) . Recently, a randomized trial showed that thiazide-type diuretics are superior in preventing major forms of cardiovascular disease compared with angiotensin-converting enzyme inhibitors and calcium-channel blockers (41). Thiazides are inexpensive and have few adverse effects (42) . Our results demonstrate that with long-term thiazide use, incidence of hip fracture can be statistically significantly reduced.
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